IFNG and vitiligo: Ritlecitinib, a JAK3/TEC inhibitor, shows therapeutic effects on alopecia areata by inhibiting IL-5 and IFN-γ (ritlecitinib may decrease the production of IFN-γ via an indirect mechanism, related to TEC kinase inhibition), which are also pathogenic cytokines in vitiligo and can therefore be used to treat this condition.